comment url,comment forum,comment keywords,comment message,comment date,comment username,comment name,paper doi,paper title,paper authors,paper date
https://www.biorxiv.org/content/10.1101/2025.07.17.665466v1#comment-6757980251,biorxivstage,0,Can you please provide more details about your image analysis pipeline? Simply citing the software won't help anyone reproduce this assay.,2025-08-26T14:13:25,disqus_wYxF71tlNf,Darren Thomson,,,,
https://www.biorxiv.org/content/10.1101/2024.03.01.582884v2#comment-6757978367,biorxivstage,1,"This preprint seems to be published on 07 May 2025, but doesn't get the link updated yet. (Tavakoli, M.R., Lyudchik, J., Januszewski, M. et al. Light-microscopy-based connectomic reconstruction of mammalian brain tissue. Nature 642, 398â€“410 (2025). https://doi.org/10.1038/s41586-025-08985-1)",2025-08-26T14:09:40,jiajun_zhang,Jiajun Zhang,,,,
https://www.biorxiv.org/content/10.1101/2025.08.13.669948v1#comment-6757879147,biorxivstage,4,"Feedbacks about your preprint : https://doi.org/10.1101/2025.08.13.669948 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data While we could access your data in OSF, we could not find any DOI. Sharing data is important for enhancing transparency and reproducibility. We encourage you to share it on a data sharing repository provided the data is not sensitive (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section.If you want more information about data sharing https://www.go-fair.org/ About Code sharing While we could access your code [interventioncontro_arm_1][code_location], we could not find any DOI. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/ Comments : During the evaluation of your preprint, I noticed the presence of a post hoc analysis. I recommend creating a dedicated section that clearly describes any protocol deviations or changes from the initial plan, in order to enhance transparency and clarity.",2025-08-26T09:35:41,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.08.08.669288v2#comment-6757878933,biorxivstage,4,"Feedbacks about your preprint : https://doi.org/10.1101/2025.08.08.669288 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data While we could access your data in OSF, we could not find any DOI. Sharing data is important for enhancing transparency and reproducibility. We encourage you to share it on a data sharing repository provided the data is not sensitive (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section.If you want more information about data sharing https://www.go-fair.org/ About Code sharing While we could access your code [interventioncontro_arm_1][code_location], we could not find any DOI. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/ Comments : Dear Author, Thank you for contributing to open science by sharing your data. To further strengthen the impact and sustainability of your work, I encourage you to: Assign a Digital Object Identifier (DOI) to your dataset, to ensure long-term accessibility and reliability of the link. Share your metadata, to facilitate the interpretation and reuse of your data. Share your study protocol, to help other researchers better understand and reproduce your work.",2025-08-26T09:34:49,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.08.07.668861v1#comment-6757878714,biorxivstage,3,"Feedbacks about your preprint : https://doi.org/10.1101/2025.08.07.668861 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data While we could access your data in supplementary data, we could not find any DOI. Sharing data is important for enhancing transparency and reproducibility. We encourage you to share it on a data sharing repository provided the data is not sensitive (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section.If you want more information about data sharing https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/.",2025-08-26T09:33:59,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.08.03.668152v1#comment-6757878242,biorxivstage,3,"Feedbacks about your preprint : https://doi.org/10.1101/2025.08.03.668152 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/.",2025-08-26T09:32:02,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.08.02.668124v1#comment-6757878019,biorxivstage,3,"Feedbacks about your preprint : https://doi.org/10.1101/2025.08.02.668124 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/.",2025-08-26T09:31:03,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.08.01.668136v1#comment-6757877777,biorxivstage,3,"Feedbacks about your preprint : https://doi.org/10.1101/2025.08.01.668136 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/.",2025-08-26T09:30:10,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.07.29.665494v1#comment-6757877517,biorxivstage,4,"Feedbacks about your preprint : https://doi.org/10.1101/2025.07.29.665494 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/. Comments : Dear authors, you state in the article that ""All data generated or analyzed during this study are included in this published article and its supplementary information files,"" but you have not shared the raw data or the code for your statistical analyses on the preprint platform, a site such as OSF, or in the supplementary materials.",2025-08-26T09:29:07,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.07.25.666761v1#comment-6757877326,biorxivstage,3,"Feedbacks about your preprint : https://doi.org/10.1101/2025.07.25.666761 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/.",2025-08-26T09:28:21,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.07.25.666825v1#comment-6757877104,biorxivstage,3,"Feedbacks about your preprint : https://doi.org/10.1101/2025.07.25.666825 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/.",2025-08-26T09:27:21,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.07.24.666513v1#comment-6757876852,biorxivstage,3,"Feedbacks about your preprint : https://doi.org/10.1101/2025.07.24.666513 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/.",2025-08-26T09:26:21,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.07.21.665920v1#comment-6757876279,biorxivstage,4,"Feedbacks about your preprint : https://doi.org/10.1101/2025.07.21.665920 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing While we could access your code [interventioncontro_arm_1][code_location], we could not find any DOI. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/ Comments : I attempted to access the data but were unable to do so using the information provided. I strongly encourage the use of a DOI to ensure easy and permanent access to the data.",2025-08-26T09:24:04,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2023.12.12.571308v4#comment-6757876062,biorxivstage,3,"Feedbacks about your preprint : https://doi.org/10.1101/2023.12.12.571308 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/.",2025-08-26T09:23:11,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.07.23.666382v1#comment-6757875770,biorxivstage,3,"Feedbacks about your preprint : https://doi.org/10.1101/2025.07.23.666382 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/.",2025-08-26T09:21:59,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.07.18.665553v1#comment-6757875470,biorxivstage,2,"Feedbacks about your preprint: https://doi.org/10.1101/2025.07.18.665553 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: you have used good research practice About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing you have used good research practice",2025-08-26T09:20:37,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.07.21.665525v1#comment-6757875245,biorxivstage,2,"Feedbacks about your preprint : https://doi.org/10.1101/2025.07.21.665525 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: you have used good research practice About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/.",2025-08-26T09:19:43,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.07.18.665472v1#comment-6757875024,biorxivstage,3,"Feedbacks about your preprint : https://doi.org/10.1101/2025.07.18.665472 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: you have used good research practice About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data While we could access your data in https://www.ebi.ac.uk/ena, we could not find any DOI. Sharing data is important for enhancing transparency and reproducibility. We encourage you to share it on a data sharing repository provided the data is not sensitive (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section.If you want more information about data sharing https://www.go-fair.org/ About Code sharing you have used good research practice Comments : Please check the availability of the data on the ENA website: an error message is obtained when searching PRJEB93986.",2025-08-26T09:18:41,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.07.17.665304v1#comment-6757874785,biorxivstage,3,"Feedbacks about your preprint: https://doi.org/10.1101/2025.07.17.665304 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/.",2025-08-26T09:17:38,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.07.17.665356v1#comment-6757874466,biorxivstage,3,"Feedbacks about your preprint: https://doi.org/10.1101/2025.07.17.665356 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/.",2025-08-26T09:16:13,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2024.12.09.627460v2#comment-6757874126,biorxivstage,3,"Feedbacks about your preprint : https://doi.org/10.1101/2024.12.09.627460 About registration: We could not find any information about the pre-registration of your study in the pre-print. Pre-registration involves documenting the hypotheses, methods, and/or analyses of a scientific study prior to its conduct (10.1073/pnas.1708274114; 10.1038/s41562-021-01269-4). If your study was pre-registered, we strongly encourage you to include the registration number in the pre-print, ideally in the abstract make this important information easy to retrieve, as this practice enhances transparency and reproducibility. If the study was not pre-registered, this should be acknowledged as a limitation. For future studies, we recommend pre-registering on an appropriate repository. About Protocol Sharing: We did not find the protocol for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a publicly available repository such as the Open Science Framework ( https://osf.io) or Zenodo ( https://zenodo.org/). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The protocol for this study is available at (link)/ in the supplementary'). Sharing your protocol will help readers better understand your study and enable them to reproduce it if they wish to test it. About the Statistical Analysis Plan Sharing: We did not find the Statistical Analysis Plan (SAP) for your study. If you have one, we encourage you to share it as supplementary material or deposit it in a repository such as the Open Science Framework ( https://osf.io). You can then include a statement in the Methods section indicating that your protocol is openly available (e.g., 'The SAP for this study is available at (link)/ in the supplementary'). Sharing your SAP will help readers better understand your study and enable them to reproduce it if they wish to test it. About Deviations and/or changes We could not find any information about potential deviations or changes to the protocol in your pre-print. Since such deviations are common, if this applies to your study, we strongly encourage you to include a subsection titled Changes to the Initial Protocol in the Methods' section and discuss these changes as a potential limitation of your results. If any deviations occurred during your study, please specify them in this new subsection. About Data sharing / FAIR Data We found insufficient information about your data sharing approach. Data should be findable, i.e. data are to assigned a globally unique and persistent identifier (for instance there is a DOI assigned to the dataset, or data are registered or indexed in a searchable resource). Data should also be accessible, i.e. data are retrievable by their identifier and can be accessed following an open, free, and universally implementable protocol. As your data id not sensitive data, we encourage you to share it openly on a data sharing repository (Dryad, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about good practices of data sharing, visit https://www.go-fair.org/ About Code sharing We could not find any information about your (statistical) code. Sharing code is important for enhancing transparency and reproducibility, especially since it does not contain sensitive information. We encourage you to openly share it on a code sharing platform (Github, Codepen, CodShare, etc.) and include the Digital Object Identifier (DOI) in the Methods section. If you want more information about Code sharing https://fair-software.nl/.",2025-08-26T09:14:53,constantvinatier,Constant VINATIER,,,,
https://www.biorxiv.org/content/10.1101/2025.08.18.670857v1#comment-6757433310,biorxivstage,2,"Thank you for sharing this excellent preprint. To support reproducibility and general 3D microscopy benchmarking (not tied to a specific project), may I request a small, de-identified sample of raw light-sheet volumes (primarily structural/reference channels; cropped/downsampled is fine)? This is for academic use only with no redistribution; Iâ€™m happy to sign a DUA and delete the data upon request or project completion. If feasible, please share a contact email or your preferred sharing method (Globus/S3/institutional storage). Minimal metadata like voxel size and channel order would be very helpful. Many thanks!",2025-08-25T13:24:45,disqus_C10L11r8gN,Chestnut,,,,
https://www.biorxiv.org/content/10.1101/2025.06.30.662308v1#comment-6757404318,biorxivstage,0,Nice extension to the Zeta test. Any plans to apply this to single-trials? Would be great to determine reponse latencies to individual trials!,2025-08-25T12:12:59,disqus_2XMQWRPUBL,Divyansh Gupta,,,,
https://www.biorxiv.org/content/10.1101/2024.09.09.612070v2#comment-6757307415,biorxivstage,1,"Comment 1 â€“ Homolog Count:  The reported number of homologous proteins appears to be incorrect. Using the EVmutation human protein dataset (Pfam ID available at https://marks.hms.harvard.edu/evmutation/human_proteins.html ), the homolog counts do not match the values presented in the manuscript. Please clarify how homologs were identified and filtered. Comment 2 â€“ Mutational Landscape: Although the EVcouplings python package allows generating a full mutational landscape, the manuscript seems to have excluded some residues selectively. This raises concerns that the mutational coverage may be biased and could affect downstream predictions. Comment 3 â€“ Single vs Double Mutations: While the study claims to evaluate only single-point mutations, two reported cases (D87A and D88A) are actually double mutations. This discrepancy should be addressed to ensure correct interpretation of the results. Comment 4 â€“ Reproducibility of Methods Sequence alignments and MM-PBSA free energy results are not reproducible with the details provided. Key parameters, input data, or scripts may be missing, making independent verification difficult. Providing full code, input files, and detailed protocols would improve reproducibility.",2025-08-25T04:43:46,disqus_VpXcVGGV0c,Abdul Basit,,,,
https://www.biorxiv.org/content/10.1101/2024.06.15.599163v3#comment-6757031758,biorxivstage,0,Now published: https://www.nature.com/articles/s42003-025-08297-0,2025-08-24T15:25:49,tsvetoslavivanov,Tsvetoslav Ivanov,,,,
https://www.biorxiv.org/content/10.1101/2025.06.05.657370v1#comment-6756429476,biorxivstage,1,"A core principle of scientific communication is that results and methods must be verifiable and reproducible. This preprint describes an undisclosed gene. Publishing anonymized findings could undermine trust in preprintsâ€”and, in my view, should not be practiced. At the very least, the disclosure that ""SB000"" is not a real gene name should be stated clearly on the front page for transparency.",2025-08-23T02:26:59,disqus_IJij91XW1k,Sergiy Velychko,,,,
https://www.biorxiv.org/content/10.1101/2024.09.21.614257v2#comment-6756113968,biorxivstage,0,I think supplementary figure after S5 are missing?,2025-08-22T14:10:57,tobias_herrmann,Tobias Herrmann,,,,
https://www.biorxiv.org/content/10.1101/2025.08.08.669361v1#comment-6755560653,biorxivstage,0,"I haven't read the entire manuscript and won't have time to until next week, but the stats are wrong.  In a 2-group test, if n=6-12 per group, then one group has 6 and the other has 12.  That's 18 mice, and df=16, not 21.  The next comparison also states df=21 with n=6 per group. for 2-sample t-test df=n-2, or 10 for the second comparison. Also, in the abstract the phrase, ""In this study we demonstrate that....improves cognitive function in AD"" should read, ""In this study we demonstrate that....improves cognitive function in a mouse model of AD""",2025-08-21T13:07:42,disqus_pgRw4DDYlN,Mike McDonald,,,,
https://www.biorxiv.org/content/10.1101/552364v3#comment-6755469677,biorxivstage,0,"Now published in Global Change Biology, 27, 4575â€“4591. https://doi.org/10.1111/gcb.15752",2025-08-21T07:50:25,thibauddecaens,Thibaud Decaens,,,,
https://www.biorxiv.org/content/10.1101/2025.02.26.640397v2#comment-6755468990,biorxivstage,0,"Now published in Science Advances, 13 Aug 2025, Vol 11, Issue 33. DOI: 10.1126/sciadv.adx4909",2025-08-21T07:46:54,thibauddecaens,Thibaud Decaens,,,,
https://www.biorxiv.org/content/10.1101/2025.08.01.668204v1#comment-6755125105,biorxivstage,0,"Hi, Nice manuscript!  But I can't find the supplementary files that are referred to in the manuscript. Best, Elin",2025-08-20T15:18:28,,Elin,,,,
https://www.biorxiv.org/content/10.1101/2025.03.06.641792v1#comment-6755086871,biorxivstage,0,"no supplementary,  no methodology part",2025-08-20T14:02:09,,hinata,,,,
https://www.biorxiv.org/content/10.1101/2024.07.19.604377v1#comment-6754737944,biorxivstage,0,"The authors present interesting information showing that a KD could enhance glutamine uptake when glucose is reduced through KD thus suggesting that glutamine targeting would be effective for managing pancreatic cancer when employed together with KD therapy. Mukherjee et al. presented a similar therapeutic strategy but with an explanation for the therapeutic effect different from that of the authorâ€™s ( https://doi.org/10.1038/s42003-019-0455-x).  It is important for the authors to address the different explanations for the similar findings in their discussion. Besides an anapleurotic explanation for the role of glutamine in driving tumor growth, the authors should also address a role for mitochondrial substrate level phosphorylation in the glutaminolysis pathway as an additional explanation for the effect ( https://doi.org/10.1080/17590914.2024.2422268). The authors assume that ketone bodies and fatty acids are critical fuel sources for pancreatic tumor cells based on their finding of labeled TCA metabolites derived from beta-hydroxybutyrate and caprylic acid. No evidence is presented showing that the pancreatic tumor cells can survive on these fuels in the absence of glucose and glutamine.  Caution is needed in considering labeled TCA metabolites as evidence for fuel utilization in the absence of viability studies. Abnormalities in mitochondria structure and function are found in pancreatic cancer (https://doi. org/ 10. 3109/ 01913 123. 2013. 788306; https:// www. ncbi. nlm. nih. gov/ pubmed/ 6185201; https:// www. ncbi. nlm. nih. gov/ pubmed/ 968802). Such abnormalities would obstruct efficient utilization of fatty acids and ketone bodies for ATP synthesis.  The authors must address the question of how ketone bodies and fatty acids can be critical fuel sources in pancreatic cancer showing abnormalities in mitochondria structure and function. Support for the authorâ€™s assumption would come from bioenergetic evidence showing that the MIA-PaCa2 cells die in hypoxia and cyanide, which would be expected for cells dependent on fatty acids & ketone bodies for fuel. No credible evidence is presented showing that the MIA-PaCa2 have normal mitochondrial function. The authors mention (reference 22) as an example of a ""push-pulse"" strategy, where a ketogenic diet nudges a system towards greater dependency on a specific metabolic program, which in turn exposes new dependencies. This paper is incorrectly cited as there is no mention of a ""push-pulse"" strategy in the paper. The correct terminology is â€œPress-Pulse and was first presented in the following paper, which is the correct citation (DOI 10.1186/s12986-017-0178-2).",2025-08-19T19:07:24,disqus_Pwi06huCe1,Eric Miller,,,,
https://www.biorxiv.org/content/10.1101/2025.07.31.667796v1#comment-6754536073,biorxivstage,0,"Nice work. A few suggestions for improvements to the optical explanations: - You suggest that the improvement in imaging depth achieved in THG in your experiments is mainly related to the wavelength used. But 1320 nm probably does not make a significant difference compared to 1150 nm. In fact, your gain compared to the other work you cite is mainly due to the use of 1 MHz OPA excitation. - You write â€œIn previous work, we showed that the intensity of the THG signal from a slab of lipid surrounded by water increases exponentially with slab thicknessâ€ -> it is actually quadratically",2025-08-19T12:25:54,emmanuel_beaurepaire,Emmanuel Beaurepaire,,,,
https://www.biorxiv.org/content/10.1101/2025.03.09.642277v3#comment-6754381895,biorxivstage,0,Will there be an update including Boltz-2 and IntelliFold?,2025-08-19T01:16:11,michaelkoksharov,Misha Koksharov,,,,
https://www.biorxiv.org/content/10.1101/2025.07.24.666639v1#comment-6754140551,biorxivstage,0,Thank you Daniel!,2025-08-18T16:28:34,,Brian Coullahan,,,,
https://www.biorxiv.org/content/10.1101/2025.03.18.643953v1#comment-6754044032,biorxivstage,0,This manuscript has now been published and can be found here: https://doi.org/10.1093/neuped/wuaf002,2025-08-18T13:24:12,thijsjmvandenbroek,Thijs J.M. van den Broek,,,,
https://www.biorxiv.org/content/10.1101/2024.09.24.614569v1#comment-6753953688,biorxivstage,0,very much information is provided,2025-08-18T08:16:39,,Rishi Raj Singh Rathore,,,,
https://www.biorxiv.org/content/10.1101/2020.09.21.305995v1#comment-6753728864,biorxivstage,0,Nice photographs. And very nice of the authors to cite Debal Deb's pioneering work with Jugal.,2025-08-17T18:35:09,debaldeb,Debal Deb,,,,
https://www.biorxiv.org/content/10.1101/2025.06.13.658955v1#comment-6753653054,biorxivstage,0,"This is a really interesting and compelling paper indicating the inner mitochondrial membrane protein ATAD3 is an essential component of the mitochondrial permeability transition pore. There is compelling evidence based on the mouse and mitochondria lacking ATAD3 where mitochondrial swelling and calcium handling are impaired and ischaemia and reperfusion injury in the heart is reduced. There is also evidence of pore-forming activity of purified ATAD3. It would be interesting to see how these mice and mitochondria with ATAD3 deleted compare to other mice and mitochondria with other putative component deletions. Also, it would be useful to know more about the ATAD3 protein used in the patch-clamping assays - how was it expressed and purified? There is also the question of the ATAD3 isoforms, how do they differ and do they all act the same.",2025-08-17T15:51:16,gavinmcstay,Gavin McStay,,,,
https://www.biorxiv.org/content/10.1101/2025.01.13.632853v1#comment-6753383982,biorxivstage,0,"You report a non-significant p-value of 0.97 in the text for the relationship between 1RM and MVC changes with muscle volume changes, but the figure correctly shows a statistically significant p-value of 0.032. The value in the figure is the correct one based on the reported sample size and r-score. Further, in your subsequent discussion, may aspects are based on this error.",2025-08-16T21:57:06,EricHelms,Eric Helms,,,,
https://www.biorxiv.org/content/10.1101/2025.07.25.666826v1#comment-6752909781,biorxivstage,0,"Congratulations on a clear, readable paper and all the solid improvements made to Casanovo v5.   I'm a happy user of Casanovo v5. I'd invite the authors to consider analyzing calibration accuracy (Figure 1a) as a function of peptide length.   Consider a 5-mer and a 10-mer peptide, each which has identical residue-level scores of 0.9 at every position.  Earlier versions computed overall scores from the arithmetic mean, and this calculation is length-independent, so the version-4-score of both the 5-mer and the 10-mer will be 0.9.  But v5, the product of the residue-level scores is used, and this is not length independent.  The v5 score will be 0.59 for the 5-mer and 0.35 for the 10-mer. The behavior of v5 might well be preferred, for many reasons!  And if a calibration curve like that in Figure 1a, but only considering short peptides, looks similar to a curve that only considers long peptides -- i.e. both short and long peptides are equally well calibrated, then the authors will have demonstrated one such reason.  Alternately, if calibration accuracy is different for short and long peptides, this would be valuable for users to know.",2025-08-15T21:11:01,tentrillion,Curt F.,,,,
https://www.biorxiv.org/content/10.1101/2025.08.01.667924v1#comment-6752862661,biorxivstage,0,"The recent work from the Hafner lab aligns closely with our own findings from 2020 and 2021 (RSC Nanoscale, 2020; iScience, 2020), which demonstrated that nanoscale regulation of APP and its proteoforms plays a critical role in disease onset. This work from Kapadia et. al. extends these insights by showing that APP not only influences synaptic transmission, but that its distinct proteoforms may act antagonistically to modulate transmission, thereby directly altering synaptic properties. https://pubs.rsc.org/en/content/articlehtml/2020/nr/d0nr00052c https://www.cell.com/iscience/fulltext/S2589-0042(20)31121-4",2025-08-15T19:40:11,disqus_Nj0QsezV3g,Deepak Nair,,,,
https://www.biorxiv.org/content/10.1101/2024.12.23.630203v1#comment-6752831954,biorxivstage,0,I think the legends are mislabeled for figure 1. The figure suggests 3/3 genotypes have more amyloid than 3/4-- the text says the reverse.,2025-08-15T18:40:06,Kool_Aid_Connoisseur,CD07,,,,
https://www.biorxiv.org/content/10.1101/2025.07.06.663161v1#comment-6752783934,biorxivstage,0,The access to the dataset (Figure 2C) requires credentials.,2025-08-15T17:01:35,,Rudian Zhang,,,,
https://www.biorxiv.org/content/10.1101/2025.07.28.667277v1#comment-6752602037,biorxivstage,0,Did you see this paper? Machine Learning on Human Muscle Transcriptomic Data for Biomarker Discovery and Tissue-Specific Drug Target Identification https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2018.00242/full,2025-08-15T09:06:18,alexzhavoronkov,Alex Zhavoronkov,,,,
https://www.biorxiv.org/content/10.1101/2025.08.01.668243v1#comment-6752532921,biorxivstage,0,Interesting work - minor error in the text: p21 is a product of the CDKN1A not CDKN2A locus :),2025-08-15T02:29:28,rahagirsalekeen,Rahagir Salekeen,,,,
https://www.biorxiv.org/content/10.1101/2025.06.27.661900v1#comment-6752270584,biorxivstage,0,I am not able to find the Supplementary material related to this article. Can I get access to it?,2025-08-14T16:00:15,disqus_fVste2vEuC,Shivangi Gupta,,,,
https://www.biorxiv.org/content/10.1101/2025.07.07.663460v2#comment-6752240102,biorxivstage,0,"Congratulations on the work! This is an impressive achievement, and it's refreshing to see a particular research community conducting a large-scale metaresearch endeavour to reflect upon itself. That said, based on these results, Iâ€™m not sure Iâ€™d jump to the conclusion that Drosophila immunity has a replication rate that is higher than in other areas. Some of the studies cited as reproducibility estimates in other fields (Amaral et al. 2025, Errington et al. 2021), as well as large-scale efforts in psychology (e.g. Open Science Collaboration, 2015) and economics (Camerer et al., 2016) that helped spur the â€œreplication crisisâ€ narrative, have relied on performing independent replications of a particular sample of publish findings. This is quite different from reviewing the literature to look for conceptual replications, as the authors do to arrive at the conclusion that most of the findings in the field are verified (i.e. around 84% of those for which a published verification attempt was found). Interestingly, for the findings which the authors do replicate independently, replicability is much lower (only 16%). Although this large discrepancy may be explained by the fact that the authors focused on unchallenged and suspicious claims (which seems to be their preferred explanation), an alternative hypothesis is that there is a huge amount of confirmation bias in the Drosophila immunity literature, either because attempts to replicate previous findings tend to reach similar results due to researcher bias, or because results that validate previous findings are more likely to be published. As I think both explanations are plausible (and, not being an expert in the field, Iâ€™d have a hard time estimating their relative probability), I think the work would be greatly strengthened if the authors tried to replicate a sample of those findings that were validated in the literature. If they arrive at a similarly high replication rate, this would strongly support the authorsâ€™ interpretation of a high replicability of findings in the Drosophila immunity literature. If replicability is much lower in the authorsâ€™ independent replications than in the published ones, on the other hand, this would suggest that the high replicability estimate obtained from the literature should be taken with a grain of salt, and could be due to a large confirmation bias problem. I obviously understand that this would be a lot of work, but I do think it would matter a lot in terms of making skeptics (including myself) agree with the claim on high replicability.",2025-08-14T14:56:42,olavoamaral,Olavo Amaral,,,,
https://www.biorxiv.org/content/10.1101/2025.08.06.668639v1#comment-6752229790,biorxivstage,0,"Good job! This study developed a high-resolution CRISPR lineage-tracing platform, eTRACER, which integrates single-cell and spatial multi-omics to reveal dynamic cellular trajectories, while avoiding target loss issues commonly caused by multi-site editing.",2025-08-14T14:35:33,,Chen Chen,,,,
https://www.biorxiv.org/content/10.1101/2025.04.02.645026v3#comment-6752224057,biorxivstage,1,"Thanks for the comment! There is indeed a reasonable amount of heterogeneity between individual replications for many of our experiments (although it is smaller than the heterogeneity between replications and original results, as shown in Table 3). That said, I can only vouch for point (a) above: labs were theoretically under no pressure to achieve a particular result. They were also blinded to the original result and, unless they had a strong intuition about it or made an effort to look it up (which we consider unlikely), should not be influenced by it. Concerning point (b), we did not fully standardize protocols across labs: when methodological details were not provided in the original experiment, we asked for each lab to fill gaps independently so as not to overstandardize to a particular choice that might not correspond to what was done originally. Labs were also free to suggest adaptations to the protocol when they thought these were required â€“ and in some cases they made quite different choices about how to deal with ambiguities or inconsistencies in the original article. Thus, part of the heterogeneity might be attributed to protocol underspecification in the original study. As the coordinator of the Initiative, I also cannot personally vouch for point (c). Although we tried to include measures to control bias in all protocols, and stimulated labs to include additional controls and checks when deemed adequate, each replication was ultimately performed in a particular lab by a different team, in the best conditions available at that facility, with no direct external supervision. Thus, I would not call those â€œvery controlled conditionsâ€ â€“ they are probably more accurately described as the â€œstandard conditions in a Brazilian academic labâ€. Protocol breaks were frequent (as shown in Fig. 5), and errors or inconsistencies in results were ocasionally detected and corrected, but there is obviously room for undetected errors or undercontrolled technical variability to affect results. Thus, I would not go so far as stating that there are intrinsic limitations to replicability in biomedical science: my conclusions would be more in the direction that â€œthere are limits to replicability in Brazilian academic biomedical labsâ€. Some of these limits could be intrinsic, but many of them likely relate to infrastructure, researcher expertise, lab organization and other issues. And while my guess that most of these issues probably hold in other countries as well, this cannot be directly extrapolated from our data.",2025-08-14T14:24:00,olavoamaral,Olavo Amaral,,,,
https://www.biorxiv.org/content/10.1101/2022.11.09.515764v1#comment-6752222089,biorxivstage,0,Published here: https://doi.org/10.1002/pld3.549,2025-08-14T14:20:04,disqus_46tdaV5vWf,J Sloan,,,,
https://www.biorxiv.org/content/10.1101/2024.09.02.610764v2#comment-6752125001,biorxivstage,0,Now published in Microbial Genomics. https://doi.org/10.1099/mgen.0.001392,2025-08-14T09:43:29,lakhansingpardeshi,Lakhansing Pardeshi,,,,
https://www.biorxiv.org/content/10.1101/2025.08.12.669671v1#comment-6751985482,biorxivstage,0,â€œOur findings suggest an experimental framework for predicting evolutionary outcomes of pathogen effector-host target interactions with implications for plant disease resistance breeding.â€ This statement at the end of the abstract and end of discussion intrigued me. I asked the question what are these implications and how could these be used in disease resistance breeding? I think the statement begs at least some explanation and discussion. If not supplied I suggest that the statement should be deleted.,2025-08-13T23:32:05,disqus_JFGgZLiZFA,Jeff Ellis,,,,
https://www.biorxiv.org/content/10.1101/2025.08.01.667173v1#comment-6751898473,biorxivstage,0,"Hi Authors, was it an Astral or Exloris 480, as stated in the abstract?",2025-08-13T19:59:00,,Roland,,,,
https://www.biorxiv.org/content/10.1101/2025.06.17.660170v1#comment-6751848366,biorxivstage,0,Conveniently missing a citation too https://pubs.rsc.org/en/Content/ArticleLanding/2025/SC/D4SC08402K which already shows hexose formation  in water microdroplets from some chemicals used. This work was published long before this work was submitted.,2025-08-13T18:16:34,disqus_rJaM2LEiOM,Robert,,,,
https://www.biorxiv.org/content/10.1101/2025.01.27.635069v1#comment-6751827501,biorxivstage,0,"Now published as: Okkelman, I.A., Zhou, H., Borisov, S.M. et al. Visualizing the internalization and biological impact of nanoplastics in live intestinal organoids by Fluorescence Lifetime Imaging Microscopy (FLIM). Light Sci Appl 14, 272 (2025). https://doi.org/10.1038/s41377-025-01949-0",2025-08-13T17:34:25,,Ruslan Dmitriev,,,,
https://www.biorxiv.org/content/10.1101/2023.12.11.571110v2#comment-6751826230,biorxivstage,0,"Now published in: ACS Nano Cite this: ACS Nano 2024, 18, 19, 12168â€“12186 https://doi.org/10.1021/acsnano.3c12539 Published April 30, 2024 https://pubs.acs.org/doi/full/10.1021/acsnano.3c12539",2025-08-13T17:31:55,,Ruslan Dmitriev,,,,
https://www.biorxiv.org/content/10.1101/2024.05.09.593421v2#comment-6751780026,biorxivstage,1,This preprint is now published in nature immunology . Please link the published article with the preprint. Article: https://www.nature.com/articles/s41590-025-02223-6,2025-08-13T15:58:57,disqus_gtBCvmIaMH,Piyush Sharma,,,,
https://www.biorxiv.org/content/10.1101/2025.07.16.665175v1#comment-6751634076,biorxivstage,0,"Interesting manuscript. Figure 4 was uploaded twice (both as Figure 4 and Figure 5), though the correct figure is uploaded in the main PDF. All the best!",2025-08-13T09:51:08,satyendramondal,Satyendra Mondal,,,,
https://www.biorxiv.org/content/10.1101/2025.07.24.666639v1#comment-6751483226,biorxivstage,1,Changing it now. Will wait to reload a full draft if and when we get reviewer comments to adjust to.,2025-08-12T22:52:53,danielkliebenstein,Daniel Kliebenstein,,,,
https://www.biorxiv.org/content/10.1101/2024.07.08.602617v1#comment-6751374173,biorxivstage,0,This work has been published in Nature Cardiovascular Research: https://www.nature.com/articles/s44161-025-00693-3,2025-08-12T18:47:17,franalvaradoguillen,Fran Alvarado Guillen,,,,
https://www.biorxiv.org/content/10.1101/2023.10.02.560091v1#comment-6751274384,biorxivstage,0,published journal version: https://onlinelibrary.wiley.com/doi/full/10.1002/pro.5239,2025-08-12T15:24:13,aleksejzelezniak,aleksejzelezniak,,,,
https://www.biorxiv.org/content/10.1101/2025.04.02.645026v3#comment-6751197115,biorxivstage,1,"I really appreciated this work â€” an in-depth analysis of replicability in science. It presents many important and interesting findings that contribute to the current discussion on reproducibility â€œcrisisâ€ and science integrity. I was particularly impressed by their report of sizable heterogeneity among the results of the replicating labs, despite the fact that (a) they were theoretically under neither publication pressure nor any other pressure from the science environment, (b) protocols and reagents were carefully checked and standardized among the labs, and (c) the experiments were conducted under very controlled conditions. Could there be intrinsic limitations to replicability in biomedical science?",2025-08-12T14:00:19,gilbenard,Gil Benard,,,,
https://www.biorxiv.org/content/10.1101/2024.05.30.596619v1#comment-6751135937,biorxivstage,0,The supplementary information is not available. no link to it.,2025-08-12T11:32:26,,Christopher,,,,
https://www.biorxiv.org/content/10.1101/2025.05.04.652153v1#comment-6751085131,biorxivstage,0,"Great work. The fact that Mrr1 also contributes to reduce the susceptibility to 5FC is interesting as it may have a clinical impact. We observed the same phenomenon in Candida parapsilosis after introducing a gain of function mutation in MRR1 (Hartuis et al., AAC 2024 PMID 38624217).",2025-08-12T08:12:30,florentmorio,Florent Morio,,,,
https://www.biorxiv.org/content/10.1101/2024.08.30.610510v2#comment-6751079950,biorxivstage,1,This preprint has now been published in Behavioral Ecology: https://doi.org/10.1093/beheco/araf071,2025-08-12T07:47:30,,ME de Jong,,,,
https://www.biorxiv.org/content/10.1101/2025.07.30.667673v1#comment-6750956274,biorxivstage,0,"Updated reference: https://doi.org/10.1021/acs.jproteome.4c01114 (published online on August 11, 2025).",2025-08-11T22:55:38,disqus_MpyEq3E4IG,Julian C,,,,
https://www.biorxiv.org/content/10.1101/2024.08.13.607807v1#comment-6750706056,biorxivstage,0,Please find the published version of the manuscript here: https://doi.org/10.1163/23524588-bja10275,2025-08-11T14:10:51,,Noah Lemke,,,,
https://www.biorxiv.org/content/10.1101/2024.01.02.573886v2#comment-6750697126,biorxivstage,1,This preprint has now been published in Cerebral Cortex: https://academic.oup.com/cercor/article/35/7/bhaf153/8185641,2025-08-11T13:51:52,jilmeier,Jil Meier,,,,
https://www.biorxiv.org/content/10.1101/2025.08.04.668575v1#comment-6750531744,biorxivstage,0,Below is the link to my review! https://zenodo.org/records/16790781,2025-08-11T03:16:21,disqus_NBEGiEjZ3s,Sean Lim,,,,
https://www.biorxiv.org/content/10.1101/2025.05.03.651999v1#comment-6750276475,biorxivstage,0,"Hallo Prathamesh and Siddharth. Thanks for sharing this pre-print. Congratulations on a detailed study of this endemic species. I agree with you that a detailed Red List assessment is necessary and this data will certainly help. In this regards, I have a few suggestions for the paper. 1. Please do not criticize earlier assessment as based on literature survey and lacking field data. Many assessments start like this, as there is often data gap due to lack of local/regional research. It is perfectly valid to conduct an assessment with available data, as the purpose of assessment is to draw attention of conservation world, not to produce a paper. There is always possibility of re-assessment, in fact there are clear rules on how to go for it in Red List system. You can notice that the assessment clearly states ""needs updating"" on the Red List site. 2. If you want to conduct this assessment, its best to first take the assessor's training course https://www.conservationtraining.org/course/ which is necessary, if not mandatory. It can clarify many key terms. 3. If you have used modelling for the assessment work, it is necessary to get it validated as per Red List norms. The guidelines are openly available. 4. Coming to the assessment, an occurrence point map is needed and you can use GeoCAT app to calculate EOO and AOO. 5. If the EOO and AOO, are fitting within EN, you need to put a proper argument for (a) or (b)(i,ii,iii,iv,v) . Do you have data to say a. Species is severely fragmented? (even if you have not collected it, it is possible and accepted to make an informed guess based on species behaviour and biology) b. If not, then it hinges on the number of locations. Please do not equate this with occurrence points or localities. There is a specific definition of ""location"" which requires proper understanding of threats. c. continuous decline in habitat quality/extent etc can be definitely argued (known the habitat well), but that argument has to be detailed and based on hard evidence. There very specific evidence based reasons as to why EOO, AOO are mapped, calculated in a specific way. So although you may have different or more detailed data or view of it, unless you are able to put it in technical manner accepted by Red List, it would not be accepted. My suggestion is complete the training course, and then start a proper assessment. I will be happy to help you with the basics, but for actually updating the assessment in the online portal, you will have to contact and work with the relevant species specialist group.",2025-08-10T14:35:13,aparnawatve,Aparna Watve,,,,
https://www.biorxiv.org/content/10.1101/2025.02.12.637621v1#comment-6750269125,biorxivstage,0,"Thank you very much, Ali. Indeed, MdaB is cytosolic. We had overlooked this characteristic and have updated it in the version for Commun Biol. Best, Chris and Nicolas",2025-08-10T14:17:11,disqus_klsqLeD3mq,Christopher Schubert,,,,
https://www.biorxiv.org/content/10.1101/2024.04.09.588702v1#comment-6750246079,biorxivstage,1,This preprint is now published in Cell Reports: https://doi.org/ 10.1016/j.celrep.2025.115330,2025-08-10T13:13:31,,Claire Meissner-Bernard,,,,
https://www.biorxiv.org/content/10.1101/2025.05.26.656196v2#comment-6749982604,biorxivstage,0,"The authors should cite DOI: 10.1038/s41594-025-01610-9, which formally proves the existence and structure of the metazoan RAVE complex, composed of DMXL1/2, WDR7, and ROGDI. This study also elucidates mRAVE's function and mechanism of action.",2025-08-09T18:48:13,,curiousresearcher1908,,,,
https://www.biorxiv.org/content/10.1101/2024.02.22.581546v2#comment-6749783865,biorxivstage,0,Now published in J Biol Chem https://www.jbc.org/article/S0021-9258(25)02429-9/fulltext,2025-08-09T08:35:22,disqus_wA9qWjHdo3,Matthew Bowler,,,,
https://www.biorxiv.org/content/10.1101/2025.05.15.653970v1#comment-6749677294,biorxivstage,0,"Dogma Check: A Salmonella T3SS-2 mutant grows fine in spleen macrophages, contradicting tissue culture dogma (PMID: 23236281). This observation was largely ignored, but here Garcia-Rodrigues et al. show that adding certain carbon sources rescues growth in cultured macrophages, hinting that T3SS-2 may be doing something entirely different in vivo.",2025-08-09T00:08:45,andreasbaumler,Andreas Baumler,,,,
https://www.biorxiv.org/content/10.1101/2025.04.03.647070v2#comment-6749511200,biorxivstage,0,"A major flaw with this work, which none of 3 eLife reviewers point out, is that they only show results until the F2 generation and claim that this independently validates ""transgenerational inheritance"". However, in the original assay the learning is carried out on adult worms with F1 embryos (and germ cells) in utero which are exposed along with the parent (P0) to the pathogen. For maternal inheritance, effects at F2 are generally still considered intergenerational (ie maternal) effects - not ""transgenerational"" epigenetic inheritance. The effect would have to be shown at F3 (and also F4 as the original Murphy study showed) for them to really claim validation of the study. I refer the authors to the following review (PMID: 24679529), cited >2000 times, on transgenerational epigenetic inheritance which clarifies this point: ""In the case of an exposed female... the fetus can be affected in utero (F1), as can the germ line of the fetus (the future F2). These are considered to be parental effects, leading to intergenerational epigenetic inheritance. Only F3 individuals can be considered as true **trans-generational ** inheritance (see Box 1), in the absence of exposure."" Given the F2 effect in this eLife study is already quite small, its imperative that the authors show F3 and F4 data to actually test the original Murphy claim. Moreover, in some of the Murphy experiments, effects at F3 and F4 are even stronger than they are at F1. So, this should not be a problem if the authors have actually replicated the Murphy results.",2025-08-08T17:10:33,reviewer6,Reviewer 6,,,,
https://www.biorxiv.org/content/10.1101/2023.11.30.567584v2#comment-6749179736,biorxivstage,0,Please note that this manuscript is now published in Journal of Experimental Botany: https://doi.org/10.1093/jxb/eraf118,2025-08-07T22:33:07,evanperkowski,Evan Perkowski,,,,
https://www.biorxiv.org/content/10.1101/2024.07.16.603789v1#comment-6748945582,biorxivstage,0,"We developed a fragment discovery algorithm some time ago for the de novo design of intrinsically disordered proteins/peptides.  As an example we targeted to HIV GP41.  (Current Enzyme Inhibition, 2017, 13, 1-7; PMCID: PMC5411995  PMID: 28503119)",2025-08-07T14:13:30,,michael peters,,,,
https://www.biorxiv.org/content/10.1101/2024.04.22.590595v1#comment-6748536990,biorxivstage,0,@bioRxiv This manuscript is now published. https://www.nature.com/articles/s41467-025-61937-1 Please add a link to the published version.,2025-08-06T17:18:29,,Swathy Babu,,,,
https://www.biorxiv.org/content/10.1101/2025.07.29.667458v1#comment-6748454700,biorxivstage,0,This is an interesting paper.,2025-08-06T14:42:59,,Bill Martin,,,,
https://www.biorxiv.org/content/10.1101/2024.11.25.625176v3#comment-6748323439,biorxivstage,0,This paper has now been published in the journal CRYOBIOLOGY. https://doi.org/10.1016/j.cryobiol.2025.105288,2025-08-06T08:18:07,AngelPerezDiz,AngelPerezDiz,,,,
https://www.biorxiv.org/content/10.1101/2024.09.10.611648v1#comment-6748297507,biorxivstage,0,"Hi Carli, sorry for the late reply. We have used between 3 and 15 mg of sediment per sample",2025-08-06T06:09:15,tonidediosmartnez,Toni de Dios MartÃ­nez,,,,
https://www.biorxiv.org/content/10.1101/2024.09.25.614855v1#comment-6748273516,biorxivstage,0,"The manuscript has been published as follows: Platelet-derived extracellular vesicle drug delivery system loaded with kaempferol for treating corneal neovascularization. Liu GS, Chen HA, Chang CY, Chen YJ, Wu YY, Widhibrata A, Yang YH, Hsieh EH, Delila L, Lin IC, Burnouf T, Tseng CL. Biomaterials. 2025 Aug;319:123205. doi: 10.1016/j.biomaterials.2025.123205. Epub 2025 Feb 24. PMID: 40023929",2025-08-06T03:48:07,gueisheungliu,Guei-Sheung Liu,,,,
https://www.biorxiv.org/content/10.1101/2024.04.03.587995v1#comment-6748132750,biorxivstage,0,"page 2 line 3   subject 'asymmetries' is plural  aux verb 'was' is singular line 12   'to'  maybe  'too' but redundant with 'also' page 3  line 1 ""Variance"" implies change... do you mean ""Difference"" or ""Divergence"" page 4 line -3 ""variables""  individual differences in non-forced ... line -1  ""lateralization, and, gap detection"" page 5 line 12  ""(DLT) is a prominent example of leftward speech lateralisation"" conflates task with outcome.  DLT is not a lateralization. line 17  ""verbal"" means 'of words, spoken, written, etc.  You mean""speech sounds"" page 6  line 3   ""the smaller the gap detection threshold"" line 23   ""Composing"" (creating ) line -2  upon individual differences in ... page 7  line 3   ""respectively, "" and another s is needed on the verb! line -7  ""have used""  imperfect past to indicate extended time page 11  line 9  ""Chance"" page 12  line -12  ""for the present study""  ""this"" is ambiguous page 13  line 8   as page 12 page 17  line -1   ""printout"" meaning ""list""? page 18  line  3   ""dichotomous""   ""dichotic""? line -4   should ""memprage "" be upper case? line -3   ""present thesis"" ""paper""? page 26  line 2    Elmer, HÃ¤nggi [84]  et al.? just after fig 3 caption something is missing (maybe overlay error) page 30   line -8   Greve et al. page 31   line 1   ""activation (measured via fMRI) to stimuli""  unclear, what stimulus property? page 32   line  ""language lateralisation positively related.""  were positively OR positively correlated? page 34    line -6 ""connectivity can each related""  missing verb or just ""relate"" page 35    line -4   ampersand? page 36    line 11   ""that less transcallosal associative"" ""fewer""  connections is a count noun page 39    line 4    ""study continues understanding""  agency problem  ""The results contribute to"" line 10   ""cortical volume is better represented by surface-area""  do you mean a better predictor of laterality, or that volume measures are of poor quality?",2025-08-05T20:31:36,disqus_Kjf6VjR6XP,Ben,,,,
https://www.biorxiv.org/content/10.1101/2025.07.21.665996v1#comment-6748098544,biorxivstage,0,wow super informative ðŸ‘ fantastic,2025-08-05T19:16:26,disqus_7uPz5HaNi4,Jacob S,,,,
https://www.biorxiv.org/content/10.1101/2025.07.20.665723v1#comment-6748081593,biorxivstage,0,Thanks Bruno!,2025-08-05T18:40:06,maciejwiatrak,Maciej Wiatrak,,,,
https://www.biorxiv.org/content/10.1101/2025.07.20.665723v1#comment-6748081384,biorxivstage,1,"Hi Alex, thanks for your comments and raising it! 1. I completely agree with you and I am super sorry it happened. The citations where there but we must have removed them during the endless rewrites. This is totally on me and I will upload a version properly crediting the work tomorrow! Also, emailed the 1st author of gLM apologising for this. Regarding benchmarking the work, we decided not to initially do that because of two reasons: 1) Key motivation for us was genome-level tasks, like phenotypic traits prediction, strain clustering, genome generation and long-range interaction prediction and as you know gLM focuses more on gene regulation and function. 2) We are very confident that scaling pLM (for example to ESM-2 650M used in gLM) would significantly boost overall results, so I feel like it would be not a fair comparison to compare the two models which use different base pLM models, and we have limited computational resources (we had access to a bunch of Intel GPUs on which we performed the training, but we no longer have access to them) and scaling up to ESM-2 650M for ~3B proteins for pretraining requires a lot of GPU hours. 2. That's a great point which we have not considered, and in retrospect I agree with you that in reality it should be treated as two separate tasks. This is something which we will introduce in the next iteration of the model/manuscript!",2025-08-05T18:39:41,maciejwiatrak,Maciej Wiatrak,,,,
https://www.biorxiv.org/content/10.1101/2024.11.01.621536v1#comment-6748052032,biorxivstage,0,"95% CI [0.02, 1.15]",2025-08-05T17:39:44,disqus_RAck56GgK5,Pedro Henrique,,,,
https://www.biorxiv.org/content/10.1101/2024.11.20.624351v1#comment-6747988503,biorxivstage,1,"Thanks for your insightful comment. As per your suggestion, we edited the introduction and fixed the citation to reflect accuracy in the final version of the paper which is now published in the Journal of Extracellular Vesicles.",2025-08-05T15:31:13,,Mona Batish,,,,
https://www.biorxiv.org/content/10.1101/2025.07.22.666180v1#comment-6747927109,biorxivstage,0,Please see two other 'rare'  prophage-driven 'complex and fundamental' effects of phage on metabolism: 1. doi:10.1111/1462-2920.15816 for prophage control of host resuscitation from the persister state and 2. doi: 10.1128/spectrum.03471-23 for a prophage protein increasing survival in bile.,2025-08-05T13:29:54,Junco7777,Prof. T. K. Wood,,,,
https://www.biorxiv.org/content/10.1101/2023.08.07.552236v1#comment-6747575582,biorxivstage,1,"Wonderful work. I wonder if you should replace most, if not all, occurrences of the word ""conserved"" with a form of the word ""identical"". ""Conserved"" (in the protein context) can mean identity or similarity, the latter being a more elastic term, that can depend on which matrix you choose and then your definition of the degree of similarity that you determine to meet your definitional threshold. Reading this preprint, I have the feeling you mean identical amino acids when you say conserved amino acids. Or maybe ""conserved"" means similar and ""fully conserved"" means identical? Would be great to clarify this. Note that we use likelihood ratios to calibrate evidence for clinical variant classification, not sensitivity and precision. In your first pass you had 4,328 & 26,006 for the P/LP variants and 245 & 16479 for the B/LB. That yields LR+ of 1.55:1 and 1/LR- of 7.25:1. That would not meet the supporting criterion (+1 Bayes conditional probability points) for pathogenic evidence. It would meet moderate evidence (-2 Bayes points) for benign evidence. When you increased stringency, you got 3,884 & 26,450 for P/LP and 102 & 16,622 for B/LB. That again does not meet the supporting threshold for pathogenic evidence (1.6:1) but it does strengthen the benign evidence with 1/LR- or 15:1 (between moderate and strong, -3 points). Not sure I am doing the math correctly from your data - feel free to correct me if I am wrong about this.",2025-08-04T18:32:32,leslie_biesecker,Leslie Biesecker,,,,
https://www.biorxiv.org/content/10.1101/776443v1#comment-6747544823,biorxivstage,0,Does anyone know if this paper was ever submitted for peer review and published?,2025-08-04T17:29:56,disqus_SzU9wk4Y4z,Jon Fisher,,,,
https://www.biorxiv.org/content/10.1101/2025.07.30.667673v1#comment-6747503351,biorxivstage,0,(Note from the corresponding author) To appear in J Prot Res.,2025-08-04T16:03:22,disqus_MpyEq3E4IG,Julian C,,,,
https://www.biorxiv.org/content/10.1101/2025.07.17.665028v1#comment-6747356576,biorxivstage,0,"The manuscript offers a paradigm example on how to address the controversially discussed use of MSC for treatmnent of OA. The authors pave the way to define scientifically grounded criteria enabling to predict clinical outcomes, connecting the spaces of cell quality and patient characteristics. The study has been carried out with a limited sample size, but should be prospectively extended with more data generated by multiple groups. This will be pivotal to develop international clinical guidelines and to dissect more indepth the mechanism of action of such treatments.",2025-08-04T09:35:07,disqus_fAkX6t4P5L,Ivan Martin,,,,
https://www.biorxiv.org/content/10.1101/2024.02.26.580534v1#comment-6747349000,biorxivstage,0,This paper has now been published in Cancer Research https://doi.org/10.1158/0008-5472.CAN-23-2814,2025-08-04T08:59:45,julian_downward,Julian Downward,,,,
https://www.biorxiv.org/content/10.1101/2025.03.14.643126v2#comment-6747114528,biorxivstage,0,This paper is now published in NAR https://doi.org/10.1093/nar/gkaf739,2025-08-03T18:34:18,,gary stormo,,,,
https://www.biorxiv.org/content/10.1101/2025.07.25.666716v1#comment-6747070559,biorxivstage,1,"There were two Rurikids named Sviatoslav III. The one that was paternal ancestor of Duke Bela of Macso belonged to the Olgovichi branch, and was the son of Vsevolod II, the Grand Prince of Kiev. The one mentioned in this preprint was the son of Vsevolod III, the Grand Prince of Vladimir. This is also confirmed by genetics, as Bela of Macso is VL11-, while Dmitry Alexandrovich is VL11+.",2025-08-03T16:43:34,disqus_gjVxU3KaUD,ÐœÐ¸Ð»Ð°Ð½ Ð Ð°Ñ˜ÐµÐ²Ð°Ñ†,,,,
https://www.biorxiv.org/content/10.1101/2025.05.22.655156v1#comment-6746781785,biorxivstage,1,"As a PhD scientist in this field, I've performed a basic peer review of this paper. This platform doesn't allow users to post under the peer reviews section, so I'm posting in the comments as others have. I couldn't paste my review here with links included properly, so here is a link to the full thing. https://www.moniquesimair.ca/insights/selenium-coal-mining-spin-vs-science",2025-08-02T21:52:44,drmoniquesimair,Dr. Monique Simair,,,,